Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

540 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia.
Vistisen D, Carstensen B, Elisabetta P, Lanzinger S, Tan EC, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Núñez J, Ha KH, Halvorsen S, Langslet G, Karasik A, Nyström T, Niskanen L, Guleria S, Klement R, Carrasco M, Foersch J, Shay C, Koeneman L, Hoti F, Farsani SF, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K; EMPRISE EU; East Asia Study Group. Vistisen D, et al. Among authors: holl rw. Cardiovasc Diabetol. 2023 Aug 31;22(1):233. doi: 10.1186/s12933-023-01963-9. Cardiovasc Diabetol. 2023. PMID: 37653496 Free PMC article.
Risk of cardiovascular events and death associated with initiation of SGLT2 inhibitors compared with DPP-4 inhibitors: an analysis from the CVD-REAL 2 multinational cohort study.
Kohsaka S, Lam CSP, Kim DJ, Cavender MA, Norhammar A, Jørgensen ME, Birkeland KI, Holl RW, Franch-Nadal J, Tangri N, Shaw JE, Ilomäki J, Karasik A, Goh SY, Chiang CE, Thuresson M, Chen H, Wittbrodt E, Bodegård J, Surmont F, Fenici P, Kosiborod M; CVD-REAL 2 Investigators and Study Group. Kohsaka S, et al. Among authors: holl rw. Lancet Diabetes Endocrinol. 2020 Jul;8(7):606-615. doi: 10.1016/S2213-8587(20)30130-3. Lancet Diabetes Endocrinol. 2020. PMID: 32559476
Empagliflozin cardiovascular and renal effectiveness and safety compared to dipeptidyl peptidase-4 inhibitors across 11 countries in Europe and Asia: Results from the EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study.
Karasik A, Lanzinger S, Chia-Hui Tan E, Yabe D, Kim DJ, Sheu WH, Melzer-Cohen C, Holl RW, Ha KH, Khunti K, Zaccardi F, Subramanian A, Nirantharakumar K, Nyström T, Niskanen L, Linnemann Jensen M, Hoti F, Klement R, Déruaz-Luyet A, Kyaw MH, Koeneman L, Vistisen D, Carstensen B, Halvorsen S, Langslet G, Fazeli Farsani S, Patorno E, Núñez J; EMPRISE Europe and Asia Study Group. Karasik A, et al. Among authors: holl rw. Diabetes Metab. 2023 Mar;49(2):101418. doi: 10.1016/j.diabet.2022.101418. Epub 2023 Jan 3. Diabetes Metab. 2023. PMID: 36608816 Free article.
Lower risk of cardiovascular events and death associated with initiation of sodium-glucose cotransporter-2 inhibitors versus sulphonylureas: Analysis from the CVD-REAL 2 study.
Goh SY, Kosiborod MN, Lam CSP, Cavender MA, Kohsaka S, Norhammar A, Birkeland KI, Holl RW, Mauricio D, Tangri N, Shaw JE, Thuresson M, Fenici P, Kim DJ; CVD-REAL Investigators and Study Group. Goh SY, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Aug;25(8):2402-2409. doi: 10.1111/dom.15092. Epub 2023 May 8. Diabetes Obes Metab. 2023. PMID: 37055714 No abstract available.
Validation of a risk prediction model for early chronic kidney disease in patients with type 2 diabetes: Data from the German/Austrian Diabetes Prospective Follow-up registry.
Kress S, Bramlage P, Holl RW, Möller CD, Mühldorfer S, Reindel J, Seufert J, Landgraf R, Merker L, Meyhöfer SM, Danne T, Fasching P, Mertens PR, Wanner C, Lanzinger S. Kress S, et al. Among authors: holl rw. Diabetes Obes Metab. 2023 Mar;25(3):776-784. doi: 10.1111/dom.14925. Epub 2022 Dec 20. Diabetes Obes Metab. 2023. PMID: 36444743
A prospective analysis of the long-term impact of the COVID-19 pandemic on well-being and health care among children with a chronic condition and their families: a study protocol of the KICK-COVID study.
Warschburger P, Kamrath C, Lanzinger S, Sengler C, Wiegand S, Göldel JM, Weihrauch-Blüher S, Holl RW, Minden K. Warschburger P, et al. Among authors: holl rw. BMC Pediatr. 2023 Mar 22;23(1):130. doi: 10.1186/s12887-023-03912-7. BMC Pediatr. 2023. PMID: 36949465 Free PMC article. Clinical Trial.
Who benefits most from outpatient lifestyle intervention? An IMI-SOPHIA study on pediatric individuals living with overweight and obesity.
Prinz N, Pomares-Millan H, Dannemann A, Giordano GN, Joisten C, Körner A, Weghuber D, Weihrauch-Blüher S, Wiegand S, Holl RW, Lanzinger S; APV initiative and the Stratification of Obesity Phenotypes to Optimize Future Therapy (SOPHIA) consortium. Prinz N, et al. Among authors: holl rw. Obesity (Silver Spring). 2023 Sep;31(9):2375-2385. doi: 10.1002/oby.23844. Epub 2023 Aug 6. Obesity (Silver Spring). 2023. PMID: 37545199
Common procedures and conditions leading to inpatient hospital admissions in adults with and without diabetes from 2015 to 2019 in Germany : A comparison of frequency, length of hospital stay and complications.
Eckert AJ, Fritsche A, Icks A, Siegel E, Mueller-Stierlin AS, Karges W, Rosenbauer J, Auzanneau M, Holl RW. Eckert AJ, et al. Among authors: holl rw. Wien Klin Wochenschr. 2023 Jul;135(13-14):325-335. doi: 10.1007/s00508-023-02153-z. Epub 2023 Feb 10. Wien Klin Wochenschr. 2023. PMID: 36763137 Free PMC article.
540 results